Articles

  • 1 day ago | womeninoptometry.com | Kyla Bazzy

    Coburn Technologies announced the addition of the Huvitz HVS-1 Vision Screener to their catalog of Huvitz product offerings. HVS-1 is a valuable tool primarily intended for pediatric use, the first of its kind among Coburn’s ophthalmic line of products. It performs rapid vision screening for infants and toddlers in less than a second with high accuracy. The device is also suitable for elderly patients and patients with mobility issues.

  • 1 day ago | womeninoptometry.com | Kyla Bazzy

    A new infographic from Contact Lens Institute™ (CLI) illustrates that while contact lenses are used by millions of people worldwide, aspects of how they are evaluated, purchased and worn may differ by country and continent. This synopsis precedes the publication of CLI’s forthcoming See Tomorrow initiative report surrounding consumer digital search behaviors, which is expected to be issued in mid-June.

  • 1 day ago | womeninoptometry.com | Kyla Bazzy

    Bausch + Lomb Corporation announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry eyes in a multi-dose bottle.  “Blink Nourish and Blink Boost deliver the same science-backed, long-lasting relief that consumers have come to rely on from our other Blink eye drop products,” said John Ferris, president, Consumer, Bausch + Lomb.

  • 2 days ago | womeninoptometry.com | Kyla Bazzy

    If you happen to be in Las Vegas, Nevada, and need a rush job on a pair of digital progressive lenses, Nataly Gammoh, OD, can get you set up in about 12 minutes. No kidding. Dr. Gammoh and her husband, licensed optician Luis Flores, have four locations in town, operating as Optika Veinte Veinte or The Eye Doc (T.E.D.). The newest one—T.E.D. Optical Lab—is a testament to fully autonomous digital optical technology.

  • 1 week ago | womeninoptometry.com | Kyla Bazzy

    Alcon has announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production.3 DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear...

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →